Ardelyx Inc (NASDAQ:ARDX) stock rose 2.23% (As on December 19, 11:28:09 AM UTC-4, Source: Google Finance) after Raymond James initiated coverage of the company, noting the company’s two early-stage launches underway for the same molecule with differentiated pricing: Ibsrela in year two of its launch (FY23 guidance $77 million at midpoint) in irritable bowel syndrome with predominant constipation (IBS-C). Newly approved Xphozah was launched in hyperphosphatemia this quarter after a successful post-CRL appeal process. The analysts Ryan Deschner and Steven Seedhouse initiate with a Strong Buy rating and a price target of $12. Although Ardelyx faced prior authorization requirements for Ibsrela access, the company introduced Ibsrela into the well-established IBS-C market and implemented its strategy to attain consistent market penetration by ensuring high levels of patient access. The prolonged absence of effective treatment choices for IBS-C patients compelled physicians to contribute to the demand for Ibsrela. Considering Ardelyx’s successful validation of its commercial strategy through the positive reception of Ibsrela, the forthcoming launch of Xphozah appears set for a significantly smoother trajectory compared to its challenging regulatory journey. Xphozah has obtained clean label without significant safety issues or boxed warnings. This achievement is expected to facilitate access for a considerable portion of patients (up to approximately 77%) with insufficient responses to phosphate binders, allowing them to acquire access through prior authorization.

Meanwhiler, the US Food and Drug Administration (FDA) approved Ardelyx’s Xphozah (tenapanor) as an add-on therapy for CKD patients on dialysis who are either intolerant of or have an inadequate response to phosphate binders. Xphozah is a phosphate absorption inhibitor which reduces serum phosphorus levels by blocking its absorption. It is administered as an oral tablet twice a day. The drug’s path to approval has been a tumultuous one. In July 2021, the FDA rejected Xphozah’s new drug application (NDA). After a successful appeal, the company filed a new NDA in April 2023. Alongside the approval, Ardelyx secured an additional $50m in debt financing from SLR Capital Partners to finance the launch of Xphozah, based on a 17 October press release. The funds will also be invested into the US commercialisation of the company’s irritable bowel with constipation therapy Ibsrela (tenapanor).

Ardelyx currently expects full-year 2023 U.S. net product revenue for IBSRELA to be between $76.0 and $78.0 million. Net income for the quarter ended September 30, 2023 was $6.6 million, or $0.03 per share, compared to net loss of $22.9 million, or $(0.14) per share, for the quarter ended September 30, 2022.